Hematopoietic cell transplantation is the predominant curative treatment for many malignant and non-malignant hematological diseases. Better pre-transplantation matching methods, treatment, and follow-up have led to increased patient survival, with nearly one million patients worldwide today living with donated hematopoietic cells. Better post-transplant follow-up further improves the quality of life for these patients, as well as reduces health care costs.
Early detection of graft rejection and disease relapse following HCT improves patient outcomes by allowing treatment to be initiated as quickly as possible after the onset of relapse. To evaluate the level of donor engraftment, mixed chimerism levels must be carefully monitored after transplantation.
In this case study from Devyser, the medical director of the Section of Transplantation Immunology at Sweden’s Karolinska University Hospital discusses how new highly sensitive and precise methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection and treatment. He also discusses why Karolinska decided to replace their STRPCR and qPCR methods with a single, NGS-based method and the benefits achieved by doing so.
Offered Free by: Devyser
See All Resources from: Devyser
This download should complete shortly. If the resource doesn't automatically download, please, click here.